CN102727686A - 一种治疗脂肪肝中药组合物 - Google Patents
一种治疗脂肪肝中药组合物 Download PDFInfo
- Publication number
- CN102727686A CN102727686A CN201210251755XA CN201210251755A CN102727686A CN 102727686 A CN102727686 A CN 102727686A CN 201210251755X A CN201210251755X A CN 201210251755XA CN 201210251755 A CN201210251755 A CN 201210251755A CN 102727686 A CN102727686 A CN 102727686A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- fatty liver
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 40
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 40
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 40
- 239000002994 raw material Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 7
- 241000180649 Panax notoginseng Species 0.000 claims description 7
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 5
- 241000207929 Scutellaria Species 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 1
- 241000092668 Artemisia capillaris Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 239000010135 fructus aurantii immaturus Substances 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000002784 stomach Anatomy 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 108700022737 rat Fat1 Proteins 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010013954 Dysphoria Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000003055 low molecular weight heparin Chemical group 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229950000628 silibinin Drugs 0.000 description 2
- 235000014899 silybin Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 241000331777 Arisaema balansae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000112598 Pseudoblennius percoides Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940019334 heparin group antithrombotic drug Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | ALT(U/L) | AST(U/L) |
正常对照组 | 31.63±5.92 | 58.38±8.54 |
模型对照组 | 275.10±70.46 | 437.24±79.21 |
水飞蓟宾组 | 196.26±39.02* | 332.54±53.54* |
低剂量组 | 78.33±16.25**##▼▼ | 94.56±9.25**##▼▼ |
中剂量组 | 61.40±13.43**##▼▼ | 81.20±7.15**##▼▼ |
高剂量组 | 57.14±15.28**##▼▼ | 76.27±5.19**##▼▼ |
组别 | 体重(g) | 肝湿重(g) | 肝指数(%) |
正常组 | 421±24 | 10.94±0.17 | 2.60±0.32 |
模型组 | 480±38 | 22.14±0.34 | 4.62±0.68¥¥ |
水飞蓟宾组 | 459±42 | 18.56±0.25 | 4.04±0.42¥¥ |
低剂量组 | 464±39 | 15.17±0.17 | 3.27±0.38¥**#▼ |
中剂量组 | 445±31 | 13.26±0.21 | 2.98±0.24**##▼▼ |
高剂量组 | 459±46 | 12.97±0.19 | 2.83±0.30**##▼▼ |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210251755.XA CN102727686B (zh) | 2012-07-20 | 2012-07-20 | 一种治疗脂肪肝中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210251755.XA CN102727686B (zh) | 2012-07-20 | 2012-07-20 | 一种治疗脂肪肝中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102727686A true CN102727686A (zh) | 2012-10-17 |
CN102727686B CN102727686B (zh) | 2015-01-14 |
Family
ID=46984450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210251755.XA Expired - Fee Related CN102727686B (zh) | 2012-07-20 | 2012-07-20 | 一种治疗脂肪肝中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102727686B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103055129A (zh) * | 2013-02-08 | 2013-04-24 | 黄晶晶 | 一种治疗高血脂症的中药制剂 |
CN103223069A (zh) * | 2013-05-20 | 2013-07-31 | 崔新明 | 一种治疗肝炎的中药组合物 |
CN103301412A (zh) * | 2013-07-07 | 2013-09-18 | 崔新明 | 一种治疗酒精肝的中药组合物 |
CN103301267A (zh) * | 2013-07-07 | 2013-09-18 | 崔新明 | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 |
CN103479691A (zh) * | 2013-09-30 | 2014-01-01 | 四川德培源中药科技开发有限公司 | 降脂保肝中药组合物 |
CN103933157A (zh) * | 2014-04-20 | 2014-07-23 | 杨军 | 一种治疗预防脂肪肝喷雾涂抹剂的制备方法 |
CN104042802A (zh) * | 2014-07-10 | 2014-09-17 | 崔新明 | 一种治疗脂肪肝的中药组合物 |
CN104225115A (zh) * | 2014-09-29 | 2014-12-24 | 上海市青浦区中医医院 | 一种治疗脂肪肝的药物及其应用 |
CN104587098A (zh) * | 2015-02-04 | 2015-05-06 | 蔡炜 | 一种治疗脂肪肝的药物 |
CN104771589A (zh) * | 2015-04-27 | 2015-07-15 | 青岛辰达生物科技有限公司 | 一种治疗脂肪肝的中药组合物及其应用 |
CN104888155A (zh) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | 一种治疗脂肪肝合并高血脂的中药组合物及其制备方法 |
CN105853691A (zh) * | 2016-06-17 | 2016-08-17 | 李登 | 一种治疗脂肪肝的中药组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1422656A (zh) * | 2002-11-07 | 2003-06-11 | 李松涛 | 治疗肝病的中药制剂 |
CN101317998A (zh) * | 2008-07-04 | 2008-12-10 | 广州蓝韵医药研究有限公司 | 治疗高血脂、脂肪肝、肝损伤的药物和制备方法 |
-
2012
- 2012-07-20 CN CN201210251755.XA patent/CN102727686B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1422656A (zh) * | 2002-11-07 | 2003-06-11 | 李松涛 | 治疗肝病的中药制剂 |
CN101317998A (zh) * | 2008-07-04 | 2008-12-10 | 广州蓝韵医药研究有限公司 | 治疗高血脂、脂肪肝、肝损伤的药物和制备方法 |
Non-Patent Citations (2)
Title |
---|
丁舸等: "中医药治疗脂肪肝研究现状", 《时珍国医国药》, vol. 18, no. 7, 31 July 2007 (2007-07-31), pages 1776 - 1778 * |
王希光: "脂肪肝中医治疗概述", 《甘肃中医》, vol. 18, no. 3, 31 March 2005 (2005-03-31), pages 40 - 42 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103055129B (zh) * | 2013-02-08 | 2013-12-18 | 黄晶晶 | 一种治疗高血脂症的中药制剂 |
CN103055129A (zh) * | 2013-02-08 | 2013-04-24 | 黄晶晶 | 一种治疗高血脂症的中药制剂 |
CN103223069A (zh) * | 2013-05-20 | 2013-07-31 | 崔新明 | 一种治疗肝炎的中药组合物 |
CN103301267B (zh) * | 2013-07-07 | 2014-11-05 | 崔新明 | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 |
CN103301267A (zh) * | 2013-07-07 | 2013-09-18 | 崔新明 | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 |
CN103301412A (zh) * | 2013-07-07 | 2013-09-18 | 崔新明 | 一种治疗酒精肝的中药组合物 |
CN103479691A (zh) * | 2013-09-30 | 2014-01-01 | 四川德培源中药科技开发有限公司 | 降脂保肝中药组合物 |
CN103479691B (zh) * | 2013-09-30 | 2015-09-02 | 四川德培源中药科技开发有限公司 | 降脂保肝中药组合物 |
CN103933157A (zh) * | 2014-04-20 | 2014-07-23 | 杨军 | 一种治疗预防脂肪肝喷雾涂抹剂的制备方法 |
CN104042802A (zh) * | 2014-07-10 | 2014-09-17 | 崔新明 | 一种治疗脂肪肝的中药组合物 |
CN104225115A (zh) * | 2014-09-29 | 2014-12-24 | 上海市青浦区中医医院 | 一种治疗脂肪肝的药物及其应用 |
CN104225115B (zh) * | 2014-09-29 | 2018-01-09 | 上海市青浦区中医医院 | 一种治疗脂肪肝的药物及其应用 |
CN104587098A (zh) * | 2015-02-04 | 2015-05-06 | 蔡炜 | 一种治疗脂肪肝的药物 |
CN104771589A (zh) * | 2015-04-27 | 2015-07-15 | 青岛辰达生物科技有限公司 | 一种治疗脂肪肝的中药组合物及其应用 |
CN104888155A (zh) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | 一种治疗脂肪肝合并高血脂的中药组合物及其制备方法 |
CN105853691A (zh) * | 2016-06-17 | 2016-08-17 | 李登 | 一种治疗脂肪肝的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102727686B (zh) | 2015-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102727686B (zh) | 一种治疗脂肪肝中药组合物 | |
CN103301412A (zh) | 一种治疗酒精肝的中药组合物 | |
CN104042802A (zh) | 一种治疗脂肪肝的中药组合物 | |
CN104013926A (zh) | 一种中药组合物及其作为脂肪肝治疗药物的应用 | |
CN103041256B (zh) | 一种治疗小儿反复呼吸道感染的中药制剂 | |
CN103301267B (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN103223069A (zh) | 一种治疗肝炎的中药组合物 | |
CN103041257B (zh) | 治疗小儿发热高烧呼吸道感染的中药制剂 | |
CN103285343B (zh) | 一种治疗肝癌的药物及其制备方法 | |
CN103041255B (zh) | 治疗小儿咽喉肿痛呼吸道感染的中药制剂 | |
CN104771589A (zh) | 一种治疗脂肪肝的中药组合物及其应用 | |
CN103393986A (zh) | 一种治疗乙肝肝硬化的中药组合物及其制备方法 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN104666999A (zh) | 一种降血压的中药配方 | |
CN104147270A (zh) | 治疗急性肝炎的中药组合物 | |
CN104352705A (zh) | 治疗乳腺小叶增生的药物组合物及其制备方法 | |
CN103041258B (zh) | 治疗小儿呼吸道感染伴纳差不食的中药制剂 | |
CN103285130B (zh) | 治疗肝癌的中药组合物及其制备方法 | |
CN105663838A (zh) | 一种联合硬膜外麻醉治疗胆总管结石的中药及制备方法 | |
CN103041259B (zh) | 治疗小儿痰多咳嗽呼吸道感染的中药制剂 | |
CN104800573A (zh) | 一种治疗肝癌的中药组合物及其制备方法 | |
CN104306565A (zh) | 治疗气滞血瘀型心绞痛的中药制剂及制备方法 | |
CN104510912B (zh) | 一种治疗气滞血瘀型慢性乙型肝炎的中药及制备方法 | |
CN104096212A (zh) | 一种治疗心肌梗死的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LI WEILI Free format text: FORMER OWNER: YANG XIANHUA Effective date: 20130328 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Su Jingrong Inventor before: Miao Yiwen |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MIAO YIWEN TO: SU JINGRONG Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130328 Address after: Jimo City, Shandong province 266200 Jhengtong street Qingdao City No. 20 Applicant after: Li Weili Address before: 276017, Shandong Linyi hi tech Industrial Development Zone Innovation Building Di Di science and Technology Information Service Center Applicant before: Yang Xianhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIMEN FENGCHENG TOURIST ATTRACTIONS DEVELOPMENT C Free format text: FORMER OWNER: LI WEILI Effective date: 20150409 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226100 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150409 Address after: Yu Dong Wenfeng road 226100 Jiangsu Haimen city of Nantong Province Patentee after: Haimen Fengcheng tourist attractions development Co., Ltd. Address before: Jimo City, Shandong province 266200 Jhengtong street Qingdao City No. 20 Patentee before: Li Weili |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150114 Termination date: 20150720 |
|
EXPY | Termination of patent right or utility model |